CONFERENCES

      German Conference on Bioinformatics

      German Conference on Bioinformatics (GCB) is an annual event that focuses on the latest developments in bioinformatics research and practice in Germany, with topics ranging from data analysis to algorithm development. The conference is aimed at bioinformaticians, researchers, and other professionals involved in the study and application of bioinformatics, and provides a forum for sharing knowledge and collaborating on new approaches to bioinformatics.

      GCB Conference 2018

      Date

      Sep 25, 2018 - Sep 28, 2018

      Location

      Vienna, Austria

      Meant as a platform for the German and European bioinformatics community, the conferences attracts a multinational audience with 250 – 300 participants each year and is open to all fields of bioinformatics.

      See related posters

      GCB Conference 2010

      Date

      Sep 20, 2010 - Sep 22, 2010

      Location

      Braunschweig, Germany

       Besides the keynote lectures, the scientific program of the German Conference on Bioinformatics 2018 is comprised of 22 contributed talks presenting 12 regular and 10 short papers. 

      See related posters

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.